Impact of voriconazole/posaconazole on CsA in paediatric allogeneic haematopoietic stem cell transplantation recipients: A real‐world study
British Journal of Clinical Pharmacology · 2026
DOI: 10.1002/bcp.70609 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Meng-Meng Jia und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Voriconazole, Triazoles, Hematopoietic Stem Cell Transplantation, Immunosuppressive Agents. Die Arbeit nennt 34 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Henan Province Medical Science and Technology Tackling Key Problems Provincial and Ministerial Joint Construction Youth Project, Henan Provincial Science and Technology Research Project.
Abstract (Originalsprache)
Aims
The aim of this study is to investigate the key factors influencing the extent of DDI between cyclosporine A (CsA, GtoPdb Ligand ID: 2162) and voriconazole (VCZ, GtoPdb Ligand ID: 6424)/posaconazole (PCZ, GtoPdb Ligand ID: 6426) in Chinese paediatric allo‐HSCT recipients and to establish evidence‐based dose adjustment strategies.
Methods
One‐hundred‐four children were enrolled and already taking stable doses of oral CsA when voriconazole or posaconazole was initiated. Evaluate the CsA dose and body weight‐adjusted dose‐normalized concentration (C/D) required to achieve therapeutic trough concentration (Cmin) before and after initiation of voriconazole or posaconazole.
Results
CsA C/D increased by 173.37% during VCZ co‐therapy and 132.90% during PCZ co‐therapy. The magnitude of change in CsA C/D was significantly associated with CYP2C19 (GtoPdb Enzyme ID: 1043) genotype and PCZ Cmin. For maintaining therapeutic CsA exposure, the required percentage reduction in CsA dose varied according to CYP3A5 (GtoPdb Enzyme ID: 1040) genotype and age. In the VCZ group, dose reductions ranged from 22.22% to 43.47% across age and CYP3A5 genotype subgroups. In the PCZ group, dose reductions ranged from 12.77% to 33.34% across corresponding subgroups.
Conclusion
CYP2C19 genotype and PCZ Cmin independently affect the magnitude of the DDI between CsA and VCZ/PCZ in paediatric allo‐HSCT patients, and CYP3A5 genotype and age of children should be integrated to guide individualized CsA dose reduction when co‐administered with VCZ or PCZ.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Henan Engineering Research Center for Application and Translation of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, China.
- Department of Pediatrics, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
ORCID-Profile: Meng-Meng Jia
Förderung
- National Key Research and Development Program of China
- Henan Province Medical Science and Technology Tackling Key Problems Provincial and Ministerial Joint Construction Youth Project
- Henan Provincial Science and Technology Research Project
- National Basic Research Program of China
Zitieren
APA
Jia, M. M., Wang, D., & Yang, J. (2026). Impact of voriconazole/posaconazole on CsA in paediatric allogeneic haematopoietic stem cell transplantation recipients: A real‐world study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70609
Vancouver
Jia MM, Wang D, Yang J. Impact of voriconazole/posaconazole on CsA in paediatric allogeneic haematopoietic stem cell transplantation recipients: A real‐world study. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70609
BibTeX
@article{Jia2026,
author = {Jia, Meng-Meng and Wang, Dao and Yang, Jing},
title = {Impact of voriconazole/posaconazole on CsA in paediatric allogeneic haematopoietic stem cell transplantation recipients: A real‐world study},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70609}
}
EUVIMED